Prognostic impact of tace combined with sorafenib or lenvatinib followed by regorafenib in recurrent hepatocellular carcinoma after liver transplantation: a retrospective study

Prognostic impact of tace combined with sorafenib or lenvatinib followed by regorafenib in recurrent hepatocellular carcinoma after liver transplantation: a retrospective study

Abstract Background Tumor recurrence after liver transplantation (LT) for hepatocellular carcinoma (HCC) remains a significant challenge. This study systematically evaluates the efficacy and safety of transarterial chemoembolization (TACE) combined with tyrosine kinase inhibitors (TKIs) for post-LT...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhao-dan Ye, Meng-chen Song, Al-Kalei AMA, Li Zhuang, Yan Zhang, Sheng-li Ye, He-miao Shi, Si-yi Zhong, Dan Zhu, Guo-hong Cao, Jing-feng Zhang
Format: Article
Language:English
Published: BMC 2025-07-01
Series:BMC Cancer
Subjects:
Hepatocellular carcinoma
Transarterial chemoembolization
Liver transplantation
Recurrence
Tyrosine kinase inhibitors
Online Access:https://doi.org/10.1186/s12885-025-14446-9
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12885-025-14446-9

Similar Items